Patent Yard Sign in
Expired Canadian patentCanada

7-oxabicycloheptane substituted diacid diamide prostaglandin analogs

CA 1286679 C · Owner: Reid, Joyce A. · Inventors: Nakane, Masami; Reid, Joyce A.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

New 7-oxabicycloheptane substituted diacid diamide prostaglandin analogs are cardiovascular agents useful, for example, in the treatment of thorombotic disease and have the structural formula including all stereoisomers thereof, wherein m is 0 to 4; A is -CH=CH- or -CH2-CH2-; n is 1 to 5; Q is -CH=CH-, -CH2-, , , , or a single bond; R is-CO2H,-CO2alkyl -CO2alkali metal,-CO2polyhydroxyamine salt -CH2OH, , or -?NR4R5 wherein R4 and R5 are the same or different and are H, lower alkyl hydroxy, lower alkoxy or aryl, at least one of R4 and R5 being other than hydroxy and lower alkoxy; p is 1 to 4; R1 is H or lower alkyl; q is 1 to 12; R2 and R3 are the same or different and are H, lower alkyl …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Granted July 23, 1991. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended July 23, 2008.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJuly 31, 1986
GrantedJuly 23, 1991
Term endedJuly 23, 2008
Patent numberCA 1286679 C
Classification (IPC)C07D493/08 +2 more

Timeline

Timeline From CIPO dates

19871990199319961999200220052008Application filedJuly 31, 1986Patent grantedJuly 23, 1991Term endedJuly 23, 2008

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.